CollPlant Biotechnologies (CLGN)
(Delayed Data from NSDQ)
$4.82 USD
+0.21 (4.47%)
Updated Sep 23, 2024 12:43 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CLGN 4.82 +0.21(4.47%)
Will CLGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLGN
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?
CLGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn into More Strength?
Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last?
CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?
Other News for CLGN
CollPlant Biotechnologies Ltd (CLGN) Q2 2024 Earnings Call Transcript Highlights: A Mixed Bag ...
CLGN Stock Earnings: CollPlant Biotechnologies Beats EPS, Misses Revenue for Q2 2024
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies GAAP EPS of -$0.33 misses by $0.06, revenue of $0.25M misses by $0.13M
CollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call Transcript